{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:21:35Z","timestamp":1793362895460,"version":"4.5.0"},"reference-count":59,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["SFB 1066 project B3"],"award-info":[{"award-number":["SFB 1066 project B3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-invasive biomarkers with biological rationale are needed for identifying patients with progressive metabolic dysfunction-associated steatohepatitis (MASH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To test the diagnostic performance of thrombospondin-2 (TSP2), insulin-like growth factor binding protein-7 (IGFBP7), growth differentiation factor (GDF15) and CD163, which were identified by liver transcriptomics as associated with the severity of MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective study from three European centres in patients with liver biopsy for suspected MASLD. TSP2, IGFBP7, GDF15 and CD163 were measured by ELISAs. Liver stiffness (vibration controlled transient elastography, VCTE), FIB4, Agile3 and FAST scores served as comparators. Outcomes were at-risk MASH (ARM, steatohepatitis NAS&gt;4\u2009and fibrosis stages 2\u20134) and advanced fibrosis (AF, stages 3\u20134). Combinatorial scores included fibrosis-biomarkers and clinical\/biological variables using multivariate logistic regression controlling for centres, age, body mass index (BMI) and gender. Training and validation sets were defined using a machine learning algorithm with a random split of the total cohort, for 100 iterations, and averaging of area under the receiver operating characteristic curve (AUROC) predictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>469 patients, 61% males, mean age 51.4 years, BMI 30.6\u2009kg\/m\u00b2, 44% with type 2 diabetes, 54% with hypertension, 31% with AF and 46% with ARM were included. The TSP2 AUROC for AF was 0.812 (95% CI: 0.766 to 0.859) higher than for the other biomarkers (ranging from 0.680 to 0.769, p&lt;0.001) and for the comparators (VCTE: 0.739, p&lt;0.04; FIB4: 0.726, p&lt;0.01\u2009and Agile3: 0.755, p=0.20). The TSP2 AUROC for ARM was 0.812 (95% CI: 0.758 to 0.858) higher than for other biomarkers (ranging from 0.722 to 0.748, p&lt;0.001) and comparators (FAST: 0.761, p=0.17). Combining TSP2 with clinical\/biological variables (AST, age, platelets, albumin, GGT) increased AUROCs to 0.846 (95% CI: 0.807 to 0.885) for AF and 0.845 (95% CI: 0.806 to 0.880) for ARM and was significantly more performant than all other biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum TSP2, alone or with clinical\/biological variables, potently discriminates AF and ARM in patients with MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2025-335598","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:20:21Z","timestamp":1753896021000},"page":"1226-1236","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort"],"prefix":"10.1136","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-3791","authenticated-orcid":false,"given":"Vlad","family":"Ratziu","sequence":"first","affiliation":[{"name":"Sorbonne Universite, Paris, France"},{"name":"ICAN Institute for Cardiometabolism and Nutrition, Paris, France"},{"name":"INSERM UMRS 1138 CRC, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rambabu","family":"Surabattula","sequence":"additional","affiliation":[{"name":"Institute of Translational Immunology, Johannes Gutenberg University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-4381","authenticated-orcid":false,"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[{"name":"Medical Sciences, University of Turin, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M","family":"Schattenberg","sequence":"additional","affiliation":[{"name":"Saarland University Medical Center Homburg, Germany, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Myneni","sequence":"additional","affiliation":[{"name":"Medical Sciences, University of Turin, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rosso","sequence":"additional","affiliation":[{"name":"Medical Sciences, University of Turin, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7245-4445","authenticated-orcid":false,"given":"Angelo","family":"Armandi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Division of Gastroenterology and Hepatology, University of Turin, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Pais","sequence":"additional","affiliation":[{"name":"Sorbonne Universite, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Kara","sequence":"additional","affiliation":[{"name":"ICAN Institute for Cardiometabolism and Nutrition, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Charlotte","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maharajah","family":"Ponnaiah","sequence":"additional","affiliation":[{"name":"ICAN Institute for Cardiometabolism and Nutrition, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3135-1359","authenticated-orcid":false,"given":"Detlef","family":"Schuppan","sequence":"additional","affiliation":[{"name":"Institute of Translational Immunology, Johannes Gutenberg University, Mainz, Germany"},{"name":"Research Center for Immune Therapy, Johannes Gutenberg-University, Mainz, Germany"},{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2026061204501026000_75.6.1226.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"2026061204501026000_75.6.1226.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"2026061204501026000_75.6.1226.3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"2026061204501026000_75.6.1226.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.010"},{"key":"2026061204501026000_75.6.1226.5","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061204501026000_75.6.1226.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02539-6"},{"key":"2026061204501026000_75.6.1226.7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","article-title":"an optimisation of the blood-based biomarker NIS4\u00ae technology for the detection of at-risk NASH: A prospective derivation and validation study","volume":"79","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"2026061204501026000_75.6.1226.8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2023.10.038","article-title":"NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"key":"2026061204501026000_75.6.1226.9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200113045"},{"key":"2026061204501026000_75.6.1226.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2014.01.013"},{"key":"2026061204501026000_75.6.1226.11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.matbio.2019.03.002","article-title":"Thrombospondin-2 regulates extracellular matrix production, LOX levels, and cross-linking via downregulation of miR-29","volume":"82","author":"Calabro","year":"2019","journal-title":"Matrix Biol"},{"key":"2026061204501026000_75.6.1226.12","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.140.2.419"},{"key":"2026061204501026000_75.6.1226.13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071540","article-title":"Thrombospondins: A Role in Cardiovascular Disease","volume":"18","author":"Chistiakov","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2026061204501026000_75.6.1226.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104296","article-title":"The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling","volume":"85","author":"Ackermann","year":"2022","journal-title":"EBioMedicine"},{"key":"2026061204501026000_75.6.1226.15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31995"},{"key":"2026061204501026000_75.6.1226.16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/cen.15010","article-title":"Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes","volume":"100","author":"Mak","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026061204501026000_75.6.1226.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.029"},{"key":"2026061204501026000_75.6.1226.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.026"},{"key":"2026061204501026000_75.6.1226.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-48956-0","article-title":"Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD","volume":"15","author":"Verschuren","year":"2024","journal-title":"Nat Commun"},{"key":"2026061204501026000_75.6.1226.20","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000586","article-title":"Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis","volume":"8","author":"Lai","year":"2024","journal-title":"Hepatol Commun"},{"key":"2026061204501026000_75.6.1226.21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s42255-019-0044-9","article-title":"Liver macrophages regulate systemic metabolism through non-inflammatory factors","volume":"1","author":"Morgantini","year":"2019","journal-title":"Nat Metab"},{"key":"2026061204501026000_75.6.1226.22","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12126"},{"key":"2026061204501026000_75.6.1226.23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa792"},{"key":"2026061204501026000_75.6.1226.24","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S451398"},{"key":"2026061204501026000_75.6.1226.25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11010-023-04743-x","article-title":"GDF15 as a key disease target and biomarker: linking chronic lung diseases and ageing","volume":"479","author":"Wan","year":"2024","journal-title":"Mol Cell Biochem"},{"key":"2026061204501026000_75.6.1226.26","doi-asserted-by":"crossref","unstructured":"Li Y , Zhang J , Chen S , et al . Growth differentiation factor 15: Emerging role in liver diseases. Cytokine 2024;182. doi:10.1016\/j.cyto.2024.156727","DOI":"10.1016\/j.cyto.2024.156727"},{"key":"2026061204501026000_75.6.1226.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0082-x"},{"key":"2026061204501026000_75.6.1226.28","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.615599","article-title":"Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis","volume":"7","author":"Gantzel","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2026061204501026000_75.6.1226.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.11.023"},{"key":"2026061204501026000_75.6.1226.30","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/liv.13150","article-title":"The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease","volume":"36","author":"Kazankov","year":"2016","journal-title":"Liver Int"},{"key":"2026061204501026000_75.6.1226.31","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s42255-023-00775-1","article-title":"A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures","volume":"5","author":"Govaere","year":"2023","journal-title":"Nat Metab"},{"key":"2026061204501026000_75.6.1226.32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"2026061204501026000_75.6.1226.33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317334"},{"key":"2026061204501026000_75.6.1226.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.10.034"},{"key":"2026061204501026000_75.6.1226.35","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.043"},{"key":"2026061204501026000_75.6.1226.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029349"},{"key":"2026061204501026000_75.6.1226.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.012"},{"key":"2026061204501026000_75.6.1226.38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/liv.14776","article-title":"Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD","volume":"41","author":"Kimura","year":"2021","journal-title":"Liver Int"},{"key":"2026061204501026000_75.6.1226.39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/liv.15792","article-title":"Thrombospondin 2 is a key determinant of fibrogenesis in non-alcoholic fatty liver disease","volume":"44","author":"Kimura","year":"2024","journal-title":"Liver Int"},{"key":"2026061204501026000_75.6.1226.40","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0131"},{"key":"2026061204501026000_75.6.1226.41","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00339.2018"},{"key":"2026061204501026000_75.6.1226.42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910574","article-title":"miR-29a-3p\/THBS2 Axis Regulates PAH-Induced Cardiac Fibrosis","volume":"22","author":"Hsu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026061204501026000_75.6.1226.43","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-023-03449-7","article-title":"Exosomal miR-17-5p from human embryonic stem cells prevents pulmonary fibrosis by targeting thrombospondin-2","volume":"14","author":"Liu","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"2026061204501026000_75.6.1226.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2036205"},{"key":"2026061204501026000_75.6.1226.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"2026061204501026000_75.6.1226.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7"},{"key":"2026061204501026000_75.6.1226.47","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061204501026000_75.6.1226.48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J Hepatol"},{"key":"2026061204501026000_75.6.1226.49","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jhep.2022.07.020","article-title":"Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD","volume":"77","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"key":"2026061204501026000_75.6.1226.50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.32145","article-title":"Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"75","author":"Tamaki","year":"2022","journal-title":"Hepatology"},{"key":"2026061204501026000_75.6.1226.51","doi-asserted-by":"crossref","first-page":"e3230","DOI":"10.1210\/clinem\/dgac292","article-title":"Serum Thrombospondin-2 Levels Are Closely Associated With the Severity of Metabolic Syndrome and Metabolic Associated Fatty Liver Disease","volume":"107","author":"Wu","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061204501026000_75.6.1226.52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1536\/ihj.18-246","article-title":"Thrombospondin-2 as a Potential Risk Factor in a General Population","volume":"60","author":"Morikawa","year":"2019","journal-title":"Int Heart J"},{"key":"2026061204501026000_75.6.1226.53","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1366-y"},{"key":"2026061204501026000_75.6.1226.54","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1007\/s11695-018-3191-2","article-title":"A Screening Study of Potential Carcinogen Biomarkers After Surgical Treatment of Obesity","volume":"28","author":"de Siqueira","year":"2018","journal-title":"Obes Surg"},{"key":"2026061204501026000_75.6.1226.55","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.humpath.2009.10.025","article-title":"A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C","volume":"41","author":"Charlotte","year":"2010","journal-title":"Hum Pathol"},{"key":"2026061204501026000_75.6.1226.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70364-7"},{"key":"2026061204501026000_75.6.1226.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.008"},{"key":"2026061204501026000_75.6.1226.58","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32475"},{"key":"2026061204501026000_75.6.1226.59","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2022.01.011","article-title":"Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD","volume":"76","author":"Brunt","year":"2022","journal-title":"J Hepatol"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2025-335598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:51:41Z","timestamp":1781265101000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2025-335598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,12]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/gutjnl-2025-335598"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2025-335598","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}